Julphar to Launch Wearable Insulin Delivery Device in GCC

- Exclusive distribution agreement signed with US medical technology company, Valeritas

- ‘High-tech device will help empower diabetes sufferers to take control of their condition,’ says Julphar GM

 

Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has signed an exclusive distribution agreement with medical technology company Valeritas Holdings, Inc. to bring its V-Go® Wearable Insulin Delivery device to the GCC.  

 

The device is an all-in-one, wearable insulin delivery option for patients with diabetes. Under the terms of the agreement, Julphar will have the rights to promote, market and sell the product to diabetes clinics and patients in the GCC. Julphar will be responsible for all sales, marketing, customer support and distribution activities in the region while Valeritas will retain responsibility for product development, regulatory approval, quality management and manufacturing.

 

Commenting on the announcement, Jerome Carle, General Manager of Julphar, said, “The prevalence of diabetes in the GCC is among the highest in the world. As a leader in the manufacture of insulin, Julphar has a responsibility to not only raise awareness of the risk factors but to provide effective solutions. 

 

“We are always exploring new, innovative and affordable options such as mobile tech, wearables and other tools, so partnering with Valeritas to bring the wearable V-Go® to the region made perfect sense. The high-tech device will help empower diabetes sufferers to take control of their condition and manage their own day-to-day care.”

 

With today’s announcement, Valeritas now has V-Go® distribution agreements in place covering 14 countries and territories. In addition to the Middle East countries, executed distribution agreements include Australia, Austria, the Czech Republic, Germany, Italy, Puerto Rico, Slovenia, and New Zealand.  Separately, Valeritas recently announced it has started the process to gain regulatory approval for V-Go® in China. 

 

John Timberlake, CEO and President of Valeritas, said: “Diabetes is now a worldwide epidemic. Currently, 425 million people suffer with diabetes, and that number is expected to grow to 629 million.

 

“For many patients with diabetes around the world, being able to adhere to a daily insulin routine of multiple injections using insulin pens and syringes is a significant challenge. Valeritas has consistently demonstrated in clinical studies that patients who switched from injection therapy to the wearable V-Go® significantly lowered blood glucose and used less insulin. 

 

“V-Go® is discrete, simple-to-use, cost-effective, clinically proven, and the only disposable, daily insulin delivery option available today. Partnering with Julphar, we are excited with the prospect of making V-Go® available to diabetes patients in the GCC.”